The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

Wave Life Sciences used RNA editing to treat α-1 antitrypsin deficiency (AATD), an inherited disorder. In patients suffering ...

Development in RNA interference (RNAi) and antisense oligonucleotide (ASO) technologies underpins the growth, as they provide ...

Gene therapy for some diseases, including Duchenne muscular dystrophy (DMD), can be tricky because the needed gene is often ...

Novartis has acquired Kate Therapeutics for up to $1.1 billion, the companies said today, in a deal that expands the buyer’s ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics, a clinical-stage biotech firm focused on RNA therapies, is poised ...

Shares of Avidity Biosciences RNA rose more than 12% on Wednesday after the company announced that it is expanding its ...

Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in ...

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.

Concurrent DNA and RNA sequencing revealed 15.3% more patients with actionable variants than DNA sequencing alone.